Company profile
Phibro Animal Health Corporation
NASDAQ: PAHC · Healthcare · Drug Manufacturers - Specialty & Generic
PublicHQ Teaneck, NJCIK 0001069899Reports USD
#135 of 1,422 Healthcare companies by revenue71st-percentile growth
EA Score
76B+FH 79DQ 72GM 72SS 76
v0.1 · 65/100 weight · provisional
↑ return on equity, filing timeliness · ↓ balance-sheet leverage, disclosure history
Methodology →Revenue TTM
$1.5B
Rev growth YoY (TTM)
+26.0%
Net income (FY)
$48.3M
Employees
2,475
as of 2026-08-10
Market cap
$1.4B
as of 2026-08-10
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$1.3B$1.3B2025
Net income$48.3M$48.3M2025
Operating income$110.5M$110.5M2025
Total assets$1.4B$1.4B2025
Liabilities$1.1B$1.1B2025
Equity$285.7M$285.7M2025
Revenue trend
FY2019 – FY2025 · USD
FY19
FY19
FY22
FY22
FY22
FY23
FY24
FY25
Revenue by segment
Filed disclosures · FY2025
By product
Vaccines100%
By geography
UNITED STATES57%
Latin America and Canada23%
EMEA12%
Asia Pacific8%
The read
What is Phibro Animal Health Corporation’s revenue?
Phibro Animal Health Corporation booked $1.3B in FY2025 revenue, growing 27% year over year — faster than most Healthcare companies we track, at a 3.7% net margin.
Peers · Healthcare
CONMED Corporation83B+Haemonetics Corporation79B+HealthEquity, Inc.83B+Progyny, Inc.71BTempus AI, Inc.59CCuraleaf Holdings, Inc.49DKey facts
CEODaniel Bendheim
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
HeadquartersTeaneck, NJ
ExchangeNASDAQ: PAHC
Employees2,475
IPO date2014-04-11
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.